Climb Bio, Inc.
Biotechnology company focused on discovering and developing monoclonal antibody therapeutics for immune-mediated and rare diseases. The organization advances investigational biologics through preclinical and clinical development, sponsors clinical studies across multiple disease areas, and maintains functions for CMC, quality, regulatory affairs, clinical operations, and corporate development.
Industries
Nr. of Employees
small (1-50)
Climb Bio, Inc.
Wellesley Hills, Massachusetts, United States, North America
Patents
Products
Investigational monoclonal antibody therapeutics
Pipeline of investigational monoclonal antibody therapies targeting immune-mediated diseases and conditions with limited therapeutic options.
Investigational monoclonal antibody therapeutics
Pipeline of investigational monoclonal antibody therapies targeting immune-mediated diseases and conditions with limited therapeutic options.
Services
Sponsorship and operational conduct of clinical studies to evaluate investigational therapies across multiple disease areas and phases.
Development of regulatory strategy and preparation of regulatory inputs spanning nonclinical, CMC, clinical and post-marketing considerations.
Implementation and oversight of quality management systems including GMP/GLP/GCP compliance and product testing frameworks to support clinical development.
Sponsorship and operational conduct of clinical studies to evaluate investigational therapies across multiple disease areas and phases.
Development of regulatory strategy and preparation of regulatory inputs spanning nonclinical, CMC, clinical and post-marketing considerations.
Implementation and oversight of quality management systems including GMP/GLP/GCP compliance and product testing frameworks to support clinical development.
Expertise Areas
- Monoclonal antibody development
- Clinical trial management
- CMC and process development
- Regulatory affairs and compliance
Key Technologies
- Monoclonal antibody therapeutics
- Biologics development
- CMC/process development
- GMP clinical supply
News & Updates
Press release reporting financial results for Q3 2025 and providing corporate updates.
Press release reporting financial results for Q3 2025 and providing corporate updates.